Patient engagement recognised by EURORDIS Black Pearl Company Award
European Patients' Forum welcomes recognition of patient engagement at yesterday's EURORDIS Black Pearl Company Award for EFPIA, Bayer, UCB and MSD.
The EURORDIS Black Pearl Company Award for Patient Engagement recognised yesterday the achievements of the European Federation of Pharmaceutical Industries and Associations, Bayer, UCB and MSD, highlighting in particular their leadership as a group in championing the development of patient engagement activities in a pre-competitive manner together with patient organisations within the Innovative Medicines Initiative (IMI).
“We welcome this initiative: it is indeed timely to provide a framework that allows structured, meaningful, sustainable and ethical patient engagement throughout the development of medicinal products,” says Nicola Bedlington, Secretary General of the European Patients’ Forum.
“Only working together with all stakeholders we can develop a framework that will strengthen both the understanding of stakeholders and the systems-readiness towards patient engagement across the board, and will ensure maximum synergies with other initiatives focusing on the patient’s voice in the life cycle of medicines,” she added.
More information here on the EURORDIS Black Pearl Awards.